Top Abstract Purchase Related
Home
>
Node
>
Subnode

Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia

Matsumoto, S.; Uemura, H.

Hinyokika Kiyo. Acta Urologica Japonica 54(6): 453-456

2008

ISSN/ISBN: 0018-1994
PMID: 18634445
Document Number: 616912
To investigate the mechanism of the ameliorating effect of alpha1-blocker on storage symptoms associated with benign prostatic hyperplasia (BPH), we evaluated the effect of tamsulosin on the bladder blood flow in rats with bladder outlet obstruction (BOO). BOO was produced by ligature in the part around a proximal urethra and kept for 2 weeks. Tamsulosin was subcutaneously administered with an osmotic pump for 2 weeks immediately after the BOO operation. Bladder blood flow in the sham-operated rats, the control BOO rats and the tamsulosin-treated BOO rats was measured by the fluoro-microsphere method. Bladder blood flow was significantly reduced in BOO rats compared with sham-operated rats, and tamsulosin significantly increased the bladder blood flow in BOO rats. The present results suggest that the increase in bladder blood flow by tamsulosin contributes to the improvement of storage symptoms associated with BPH.

Document emailed within 1 workday
Secure & encrypted payments

Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168
Takayama, T.; Arakawa, I.; Kakihara, H.; Tachibana, K.; Ozono, S. 2012: Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan Hinyokika Kiyo. Acta Urologica Japonica 58(2): 61-69
Magoha, G.A. 1998: Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia East African Medical Journal 75(5): 260-263
Lepor, H. 1995: Alpha blockade for the treatment of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 375-386
Lowenthal, D.T.; Flannery, M.; Mader, S.L.; Nelson, R.P. 1998: Benign prostatic hyperplasia: maximizing treatment with alpha blockers Geriatrics 53(Suppl 2): S4-28
Li, Y.-Z.; Liang, W.-N.; Zhang, G.-W.; Weng, Z.-Q.; Zhong, Y.; Xu, S.; Shang, X.-J. 2019: Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms Zhonghua Nan Ke Xue 25(11): 1001-1004
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Cornu, J-Nicolas.; Rouprêt, M. 2007: Impact of nocturia on the daily life of patients with lower urinary tract symptoms due to benign prostatic hyperplasia Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(5 Suppl 1: 1033-1036
Gao, W.-J.; Wang, Y.-M.; Wang, C.-H.; Yang, X.-K.; Wan, L.; Li, W.-P. 2013: Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications Zhonghua Nan Ke Xue 19(4): 315-320
Sun, Z.Y.; Tu, Z.H. 1998: A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia Methods and Findings in Experimental and Clinical Pharmacology 20(4): 283-287
Mahawong, P.; Chaiyaprasithi, B.; Soontrapa, S.; Tappayuthapijarn, P. 2007: A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature Journal of the Medical Association of Thailand 90(9): 1821-1827
Ben Rhouma, S.; H'sairi, M.; Adbi, H.; Binous, M.Y.; Nouira, Y.; Ben Raies, N.; Mosbah, A.T.; Horchani, A. 2015: Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia La Tunisie Medicale 93(3): 164-169
Pytel', I.A.; Lopatkin, N.A.; Gorilovskiĭ, L.M.; Vinarov, A.Z.; Sivkov, A.V.; Medvedev, A.A. 2004: The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia Urologiia 2: 3-7
Deng, Z.-X.; Ji, L.-X.; Zhang, Y.-R.; Li, C.-d.; Cai, J.; Jiang, H.-H. 2018: Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : a short-term clinical observation Zhonghua Nan Ke Xue 24(1): 72-77
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Kongkanand, A.; Chodchoy, V.; Lojanapiwat, B.; Pumpaisanchai, S.; Ratana-Olarn, K.; Sae-Tang, P.; Taweemonkongsap, T. 2009: Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Journal of the Medical Association of Thailand 92(7): 969-978
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Kupriyanov, Y.A.; Rasner, P.I.; Rokhlikov, I.M.; Akrikidi, A.A.; Soloviev, V.V.; Markov, A.A.; Nozdrin, E.V.; Logvinov, L.A.; Vasilevskiy, R.P.; Skrupskiy, K.S.; Pushkar, D.Y.; Putilovskiy, M.A.; Epstein, O.I. 2019: The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-nave patients with benign prostatic hyperplasia Urologiia 3: 36-42
Mazo, E.B.; Dmitriev, D.G. 2001: Clinical effect of the drug "Prostamol-Uno" in patients with benign prostatic hyperplasia and chronic prostatitis Urologiia 5: 38-41
Okorie, C.O.; Pisters, L.L. 2010: Effect of modified suprapubic prostatectomy for benign prostatic hyperplasia on postoperative hemoglobin levels Canadian Journal of Urology 17(4): 5255-5258